31 May 2024
Scancell Holdings
plc
("Scancell" or the "Company")
Scancell Announces its
Attendance at Upcoming Conferences
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
today confirms that it will attend and present at the upcoming
conferences listed below. Presentations at these high-profile
conferences follow the significant recent progress that Scancell
has made in developing its pipeline of innovative immunotherapies
to address unmet needs in cancer.
· BIO International
Convention, taking place in San
Diego, CA from 3-6 June.
Mandeep Sehmi, Head of Business
Development, will be attending the conference.
· Antibody
Engineering & Therapeutics Europe, taking place in London, UK from 4-6 June.
Bubacarr Gibril Kaira, Antibody
Research Scientist at Scancell, will be presenting at the
conference.
Mireille Vankemmelbeke, Principal
Scientist at Scancell, will also be attending.
Session Title: Fc Engineering and Fc
Receptor Function
Title: Unlocking the Unique
Potential of AvidiMAb® in Clustering and Signalling
Date and Time: Tuesday
4th June at 5:15pm BST
If you would like to arrange a
meeting with management, please contact commercial.enquiries@scancell.co.uk.
-ENDS-
|
For
further information, please contact:
|
|
|
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Professor Lindy Durrant,
CEO
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea/Ben
Good
|
|
|
Nick Harland (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint Broker)
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate
Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
|
|
|
ICR
Consilium
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Angela
Gray/Lindsey Neville
|
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab®
for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody® ) this includes citrullination
and homocitrullination of proteins, whereas its mAb portfolio
targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab® ) or enhances the potency of antibodies and their
ability to directly kill tumour cells (AvidiMab® ).
For further information about
Scancell, please visit: https://www.scancell.co.uk/